Valneva considering COVID-19 future

12 August 2022

French specialty vaccine company Valneva (Euronext Paris: VLA), a late-comer in the race to develop coronavirus vaccines, announced it has suspended manufacturing of VLA2001 and is exploring strategic options.

The company made the announcement alongside presenting its financial results on Thursday.

In light of the reduced order volume from European Union member states, Valneva has suspended manufacturing of the vaccine and recognized write-downs of 100.6 million euros ($104 million) as of June 30, 2022 relating to existing inventory acquired to produce and supply volumes under the original European Comission (EC) Advance Purchase Agreement (APA).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK